# Dexcom **Source:** https://geo.sig.ai/brands/dexcom **Vertical:** Healthcare Tech **Subcategory:** Enterprise **Tier:** Leader **Website:** dexcom.com **Last Updated:** 2026-04-14 ## Summary San Diego CGM diabetes technology (NASDAQ: DXCM) ~$3.9B 2024 revenue; G7 prescription CGM market leader, Stelo OTC CGM launched 2024, $75M Oura Ring investment/integration competing with Abbott FreeStyle Libre. ## Company Overview Dexcom, Inc. is a San Diego, California-based diabetes management technology company — publicly traded on NASDAQ (NASDAQ: DXCM) as an S&P 500 Health Care component — developing and commercializing continuous glucose monitoring (CGM) systems for people with Type 1 diabetes, Type 2 diabetes, and pre-diabetes through approximately 9,000 employees worldwide. Dexcom's G7 CGM system (a small wearable sensor and transmitter worn on the body that measures glucose continuously every 5 minutes without fingerstick calibration) is the market-leading prescription CGM for insulin-using patients — enabling tight glucose management that prevents hypoglycemic episodes, reduces A1c levels, and improves outcomes for the 8+ million US patients using insulin. In 2024, Dexcom launched Stelo — the first FDA-cleared over-the-counter CGM in the United States, requiring no prescription and targeting the approximately 25 million US adults with Type 2 diabetes who do not use insulin, pre-diabetes patients, and health-conscious consumers seeking metabolic insights. The Stelo OTC CGM integrates with the Oura Ring (wearable health tracking) through a strategic partnership announced in November 2024, with Dexcom investing $75 million in ŌURA and the companies launching Stelo integration in the Oura app — giving users 24/7 glucose insights alongside sleep, heart rate, and activity data from the Oura Ring. Dexcom reported full year 2024 revenue of approximately $3.9 billion, with continued CGM market penetration driving growth. Dexcom's CGM platform model creates competitive advantage through clinical accuracy, ecosystem integration, and insurance reimbursement coverage: the Dexcom G7's FDA-cleared MARD (mean absolute relative difference) accuracy of 8.2% sets the clinical standard that competing CGM systems must meet to gain formulary placement on insurance plans that cover CGM for insulin-using diabetics — and Dexcom's clinical data package (from 10+ years of G4/G5/G6/G7 real-world use) provides the payer evidence that newly entered competitors (from consumer health companies) cannot immediately replicate. The integration of Dexcom CGM data with insulin pumps (closed-loop artificial pancreas systems from Tandem Diabetes Care and Insulet OmniPod), insulin pen systems, and electronic health records creates a data-connected care ecosystem where Dexcom sits at the center of diabetes management workflow — generating value for patients, clinicians, and payers that individual CGM sensor sales alone do not capture. In 2025, Dexcom competes in continuous glucose monitoring and diabetes management technology against Abbott Laboratories (NYSE: ABT, FreeStyle Libre CGM — the global market share leader by installed user base in Type 2 diabetes), Medtronic (NYSE: MDT, Guardian 4 CGM and MiniMed insulin pump integration), and emerging consumer health CGMs from Levels, Supersapiens, and NutriSense for the prescription diabetes management market and the emerging OTC metabolic monitoring market. Stelo's OTC positioning opens the massive non-insulin Type 2 diabetes market (25M US patients) and the "metabolic wellness" consumer market — where health-conscious non-diabetics seek continuous glucose data to optimize diet, exercise, and sleep — a market where Apple Watch (NYSE: AAPL), Samsung Galaxy Watch, and Google (NASDAQ: GOOGL) have announced CGM feature development ambitions. The $75M Oura investment and Stelo-Oura integration represents Dexcom's strategy to embed CGM in the consumer wellness wearable ecosystem before big tech platforms commoditize glucose sensing. The 2025 strategy focuses on Stelo consumer market growth, G7 prescription market share maintenance, and CGM integration with GLP-1 medication management (Ozempic, Wegovy patients who benefit from CGM monitoring). ## Frequently Asked Questions ### What is Dexcom? Dexcom is a medical technology company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. Founded in 1999 and headquartered in San Diego, California, Dexcom is the global leader in CGM technology, serving approximately 2.8 to 2.9 million users worldwide with products that provide real-time glucose data to help people with diabetes make informed treatment decisions. ### When was Dexcom founded? Dexcom was founded in 1999 in San Diego, California by Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston, and Bret Megargel. The company went public on NASDAQ in April 2005 under ticker symbol DXCM and received its first FDA approval in 2006 for the Dexcom STS CGM System. ### Where is Dexcom headquartered? Dexcom is headquartered in San Diego, California, where its research and development center is also located. The company operates globally with manufacturing facilities in Mesa, Arizona, Batu Kawan, Malaysia, and Athenry, Ireland. ### What products does Dexcom offer? Dexcom offers several CGM products including the Dexcom G7 (flagship 10-day system), G7 15-Day System (extended wear), Stelo (first over-the-counter CGM for adults not using insulin), and G6 Pro (professional system for healthcare providers). All systems provide continuous glucose monitoring to help manage diabetes. ### How much revenue does Dexcom generate? Dexcom generated $4.033 billion in revenue in fiscal year 2024, representing an 11.34% increase from 2023. Q4 2024 revenue reached $1.114 billion (8% year-over-year growth), and the company reported net income of $576.20 million for the full year. ### Who are Dexcom's main competitors? Dexcom's primary competitors in the continuous glucose monitoring market include Abbott Laboratories (FreeStyle Libre system), Medtronic (Guardian CGM), and emerging CGM technology companies. Dexcom maintains market leadership through superior accuracy, smartphone integration, and continuous innovation. ### What makes Dexcom different from competitors? Dexcom differentiates itself through best-in-class accuracy (8.2% MARD for G7), real-time alerts and alarms, seamless smartphone integration, the smallest form factor (G7 is 60% smaller than G6), 30-minute warmup time, and comprehensive ecosystem including the first OTC CGM (Stelo) and strategic partnerships like the ŌURA Ring integration. ### How many employees does Dexcom have? Dexcom has approximately 9,600 employees globally. The workforce is 50.3% female and 53.2% ethnic minorities, reflecting the company's commitment to diversity and inclusion in the workplace. ### What is Dexcom's market position? Dexcom is the global leader in continuous glucose monitoring technology with approximately 2.8 to 2.9 million users worldwide (25% growth in 2024). The company holds significant market share in the estimated $13.6 billion CGM market and is publicly traded on NASDAQ with a market capitalization of approximately $23-25 billion. ### What are Dexcom's recent partnerships? Dexcom announced a strategic partnership with ŌURA in November 2024, investing $75 million in ŌURA's Series D funding. This partnership enables two-way data flow between Dexcom glucose biosensors and the Oura Ring, with Stelo integration launching in May 2025 to provide 24/7 glucose insights via the Oura app. ### Is Dexcom expanding beyond diabetes? Yes, Dexcom expanded its mission in 2022 from focusing solely on diabetes to "empower people to take control of health." The 2024 launch of Stelo, available over-the-counter for people without diabetes, represents this broader vision of glucose monitoring for general health and wellness applications including prediabetes management. ### What is Dexcom's leadership transition plan? Dexcom announced in December 2024 that COO Jake Leach will become President and CEO on January 1, 2026, succeeding Kevin Sayer who has served as CEO since 2015. Sayer will transition to Executive Chairman of the Board. Leach has been with Dexcom for 21 years and was given the President title in May 2024. ## Tags b2b, healthtech, manufacturing, saas, public --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*